title: Interleukin-17 facilitates the immune suppressor capacity of high-grade glioma-derived CD4 (+) CD25 (+) Foxp3 (+) T cells via releasing transforming growth factor beta.
abstract: High-grade glioma is a malignant tumour; the pathogenesis is to be further investigated. Interleukin (IL)-17 is an inflammatory cytokine. Chronic inflammation is a pathological feature of cancer. This study aimed to characterize the glioma-derived IL-17(+) regulatory T cells (Treg). In this study, single cells were isolated from surgically removed high-grade glioma tissue and examined by flow cytometry. The immune suppressor effect of IL-17(+) Tregs on CD8(+) T cells was assessed in vitro. The results showed that abundant IL-17(+) Tregs were found in high-grade glioma tissue. The immune suppressor molecule, transforming growth factor (TGF)-beta, was detected in the IL-17(+) Tregs. The proliferation of CD8(+) T cells was suppressed by culturing with the IL-17(+) Tregs, which was partially abrogated by neutralizing antibodies of either TGF-beta or IL-17 and completely abrogated by neutralizing antibodies against both TGF-beta and IL-17. In conclusion, IL-17(+) Tregs exist in the high-grade glioma tissue; this subset of T cells can suppress CD8(+) T cell activities via releasing TGF-beta and IL-17.
authors.affiliation: Department of Neurosurgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China.
authors.forename: H
authors.initials: H
authors.lastname: Liang
authors.forename: L
authors.initials: L
authors.lastname: Yi
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: C
authors.initials: C
authors.lastname: Zhou
authors.forename: L
authors.initials: L
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation; D002648:Child; D005260:Female; D051858:Forkhead Transcription Factors / Q000096:biosynthesis; D005909:Glioblastoma / Q000276:immunology* / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents; D007249:Inflammation / Q000276:immunology; D020381:Interleukin-17 / Q000276:immunology* / Q000378:metabolism; D053645:Interleukin-2 Receptor alpha Subunit / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D053722:Receptors, Interleukin-17 / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000276:immunology* / Q000378:metabolism; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C508017:IL2RA protein, human; D007166:Immunosuppressive Agents; D020381:Interleukin-17; D053645:Interleukin-2 Receptor alpha Subunit; D053722:Receptors, Interleukin-17; D016212:Transforming Growth Factor beta